Rising Leaders

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.

Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.

It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.

Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.